Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

James R. Eshleman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9274-8459; OpenAlex author ID A5059832377; NIH RePORTER profile ID 1894081. Sources: funder_awards.

Their work

Papers
32 (first author 1, last author 8)
Trials
0
Grants
2
Labs led
1
Collaborators
129
Papers, trials and grants by year

2011: 2 papers, 1 grant · 2012: 2 papers · 2013: 1 grant · 2014: none · 2015: 4 papers · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 4 papers · 2020: 3 papers · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 32

  1. Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer. Last author DOI 10.1172/jci190121↗
  2. Reversible chemoresistance of pancreatic cancer grown as spheroids. Last author DOI 10.1080/1120009x.2024.2402177↗
  3. Spatial profiling of human pancreatic ductal adenocarcinoma reveals molecular alterations associated with venous invasion. Co-author DOI 10.1126/scitranslmed.ady7524↗
  4. Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification. Co-author DOI 10.1158/2767-9764.crc-25-0229↗
  5. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer. Co-author DOI 10.1200/jco.23.01573↗
  6. Using a CA19-9 Tumor Marker Gene Test to Assess Outcome After Pancreatic Cancer Surgery. Co-author DOI 10.1245/s10434-024-14942-5↗
  7. Screening for pancreatic cancer has the potential to save lives, but is it practical? Co-author DOI 10.1080/17474124.2023.2217354↗
  8. Morphology-guided transcriptomic analysis of human pancreatic cancer organoids reveals microenvironmental signals that enhance invasion. Co-author DOI 10.1172/jci162054↗
  9. Pancreatic cancer pathology viewed in the light of evolution. Co-author DOI 10.1007/s10555-020-09953-z↗
  10. Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures. Last author DOI 10.1097/mpa.0000000000001807↗
  11. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  12. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2019.10.036↗
  13. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Co-author DOI 10.1016/j.jmoldx.2020.02.010↗
  14. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004200↗
  15. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  16. Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic D… Co-author DOI 10.1097/mpa.0000000000001255↗
  17. Biphenotypic Differentiation of Pancreatic Cancer in 3-Dimensional Culture. Last author DOI 10.1097/mpa.0000000000001390↗
  18. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-19-0197↗
  19. Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid. Co-author DOI 10.1016/j.jmoldx.2017.09.006↗
  20. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Co-author DOI 10.1073/pnas.1720588115↗
  21. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  22. Susceptibility of ATM-deficient pancreatic cancer cells to radiation. First author DOI 10.1080/15384101.2017.1312236↗
  23. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗
  24. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-15-0402↗
  25. Transflip mutations produce deletions in pancreatic cancer. Last author DOI 10.1002/gcc.22258↗
  26. Familial and sporadic pancreatic cancer share the same molecular pathogenesis. Last author DOI 10.1007/s10689-014-9755-y↗
  27. Whole genomes redefine the mutational landscape of pancreatic cancer. Co-author DOI 10.1038/nature14169↗
  28. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Co-author DOI 10.1038/ncomms8686↗
  29. Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Last author DOI 10.1158/1078-0432.ccr-12-0827↗
  30. ATM mutations in patients with hereditary pancreatic cancer. Co-author DOI 10.1158/2159-8290.cd-11-0194↗
  31. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-10-3431↗
  32. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Co-author DOI 10.1158/1535-7163.mct-10-0893↗

Grants 2

  1. Identifying Familial Pancreatic Cancer Predisposition Genes R21CA164592↗
  2. Identifying Familial Pancreatic Cancer Predisposition Genes AWARD pancan:2011-james-eshleman-md-phd-identifying-familial-pancreatic-cancer-p

Closest collaborators

The 25 strongest of 129 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Goggins · 14 shared papers, 2011–2025 · strength 1.46
  2. Ralph H. Hruban · 17 shared papers, 2011–2026 · strength 1.44
  3. Nicholas Jason Roberts · 8 shared papers, 2012–2026 · strength 0.77
  4. Jin Peng He · 7 shared papers, 2018–2024 · strength 0.75
  5. Alison P. Klein · 10 shared papers, 2011–2023 · strength 0.70
  6. Richard Andrew Burkhart · 6 shared papers, 2019–2024 · strength 0.69
  7. Christopher Lee Wolfgang · 7 shared papers, 2016–2025 · strength 0.62
  8. Laura DeLong Wood · 5 shared papers, 2016–2025 · strength 0.59
  9. Marcia Irene Canto · 5 shared papers, 2018–2024 · strength 0.57
  10. Robert A. Anders · 2 shared papers, 2025–2026 · strength 0.44
  11. Amanda L. Blackford · 3 shared papers, 2012–2024 · strength 0.40
  12. Takeichi Yoshida · 2 shared papers, 2024 · strength 0.37
  13. Yohei Ando · 2 shared papers, 2024 · strength 0.37
  14. Helena Saba · 2 shared papers, 2024 · strength 0.37
  15. Elizabeth Abou Diwan · 2 shared papers, 2024 · strength 0.37
  16. Anne Marie Lennon · 2 shared papers, 2023–2024 · strength 0.35
  17. Elana Judith Fertig · 2 shared papers, 2023–2025 · strength 0.34
  18. Alexis L. Norris · 4 shared papers, 2015–2025 · strength 0.34
  19. Yoshihisa Matsushita · 2 shared papers, 2019–2025 · strength 0.29
  20. Seung‐Mo Hong · 3 shared papers, 2011–2021 · strength 0.24
  21. Elliot K. Fishman · 2 shared papers, 2019–2023 · strength 0.24
  22. Selina Shiqing K. Teh · 1 shared paper, 2026 · strength 0.23
  23. Jun Yu · 4 shared papers, 2012–2020 · strength 0.23
  24. Toshiya Abe · 3 shared papers, 2018–2020 · strength 0.22
  25. Jacquelyn W. Zimmerman · 2 shared papers, 2020–2023 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.